{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-034464","form_type":"8-K","ticker":"KYTX","cik":"0001994702","company_name":"Kyverna Therapeutics, Inc.","filed_at":"2026-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.950591+00:00","generated_at":"2026-05-16T05:25:29.980674+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kyverna appoints Mayo Pujols as CTO; Karen Walker retires effective Feb 9, 2026","bullets":["Mayo Pujols named CTO effective Feb 9, bringing 30+ years in CAR T and cell therapy manufacturing.","Outgoing CTO Karen Walker retires; will consult on BLA submission for miv-cel in stiff person syndrome.","Pujols receives an inducement option for 300,000 shares vesting over 4 years under the 2024 Inducement Plan.","The inducement plan was amended to increase authorized shares by 1,000,000 to 5,000,000 total.","Kyverna advances toward potential commercial launch of miv-cel for autoimmune diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-034464","json":"https://secwatch.observer/filing/0001193125-26-034464.json","markdown":"https://secwatch.observer/filing/0001193125-26-034464.md","text":"https://secwatch.observer/filing/0001193125-26-034464.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1994702/000119312526034464/0001193125-26-034464-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1994702/000119312526034464/kytx-20260129.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T05:25:29.980674+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}